A PET study in healthy subjects of brain exposure of
Acrylamides
/ administration & dosage
Adult
Aniline Compounds
/ administration & dosage
Antineoplastic Agents
/ administration & dosage
Blood-Brain Barrier
/ metabolism
Brain
/ diagnostic imaging
Brain Neoplasms
/ drug therapy
Carbon Radioisotopes
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Healthy Volunteers
Humans
Injections, Intravenous
Magnetic Resonance Imaging
/ methods
Male
Middle Aged
Positron-Emission Tomography
/ methods
Tissue Distribution
Brain metastasis
PET
blood–brain barrier
epidermal growth factor receptor
microdose
Journal
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
ISSN: 1559-7016
Titre abrégé: J Cereb Blood Flow Metab
Pays: United States
ID NLM: 8112566
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
pubmed:
23
4
2019
medline:
15
12
2020
entrez:
23
4
2019
Statut:
ppublish
Résumé
Osimertinib is a tyrosine kinase inhibitor (TKI) of the mutated epidermal growth factor receptor (EGFRm) with observed efficacy in patients with brain metastases. Brain exposure and drug distribution in tumor regions are important criteria for evaluation and confirmation of CNS efficacy. The aim of this PET study was therefore to determine brain distribution and exposure of
Identifiants
pubmed: 31006308
doi: 10.1177/0271678X19843776
pmc: PMC7168784
doi:
Substances chimiques
Acrylamides
0
Aniline Compounds
0
Antineoplastic Agents
0
Carbon Radioisotopes
0
Carbon-11
0
osimertinib
3C06JJ0Z2O
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
799-807Références
Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1639-50
pubmed: 19437012
Cancer Discov. 2014 Sep;4(9):1046-61
pubmed: 24893891
Drug Metab Dispos. 2016 Aug;44(8):1201-12
pubmed: 27226351
J Clin Oncol. 2018 Aug 28;:JCO2018783118
pubmed: 30153097
Brain Res Dev Brain Res. 1991 Jun 21;60(2):145-54
pubmed: 1893564
Clin Cancer Res. 2010 Dec 1;16(23):5873-82
pubmed: 21030498
Medicine (Baltimore). 2017 Feb;96(6):e6087
pubmed: 28178168
Front Oncol. 2014 Sep 15;4:248
pubmed: 25309873
Int J Neuropsychopharmacol. 2015 Mar 26;18(10):pyv036
pubmed: 25813017
Lung Cancer. 2015 Apr;88(1):108-11
pubmed: 25682925
Lung Cancer. 2017 Dec;114:68-69
pubmed: 29173769
PLoS Med. 2005 Mar;2(3):e73
pubmed: 15737014
J Med Chem. 2014 Oct 23;57(20):8249-67
pubmed: 25271963
Clin Cancer Res. 2016 Oct 15;22(20):5130-5140
pubmed: 27435396
Neuroimage. 2009 Apr 15;45(3):891-902
pubmed: 19136064
EJNMMI Res. 2017 Aug 18;7(1):66
pubmed: 28822101
J Histochem Cytochem. 1988 Jan;36(1):81-6
pubmed: 3275713
J Cereb Blood Flow Metab. 1989 Oct;9(5):696-708
pubmed: 2528555
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Oncotarget. 2018 Mar 8;9(20):15418-15434
pubmed: 29632655
Cancer. 2010 Mar 1;116(5):1155-64
pubmed: 20087963
Oncologist. 2018 Oct;23(10):1199-1209
pubmed: 29650684
J Clin Oncol. 2018 Sep 10;36(26):2702-2709
pubmed: 30059262
Radiology. 2007 Mar;242(3):882-8
pubmed: 17229875
Oncol Res Treat. 2016;39(7-8):461-3
pubmed: 27486808
Radiat Oncol. 2011 Nov 25;6:166
pubmed: 22118497
J Pharmacokinet Pharmacodyn. 2013 Jun;40(3):267-79
pubmed: 23660778
Clin Pharmacol Drug Dev. 2019 Feb;8(2):198-207
pubmed: 29683562